Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial

Journal:

Nature Communications

Published:

2026-03-14

DOI:

10.1038/s41467-026-69965-1

Affiliations:

61

Authors:

65

Go to article

Institutions	Authors	Share
Akeso, Inc, China	6.000000	0.09
Xiangya Hospital, CSU, China	2.000000	0.03
Fujian Medical University, China	1.000000	0.02
Cancer Hospital of Yunnan Province, China	1.000000	0.02
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.02
Affiliated Hospital of Southwest Medical University, China	1.000000	0.02
Tianjin Medical University Cancer Institute and Hospital, TMU, China	1.000000	0.02
Fourth Hospital of Hebei Medical University, China	1.000000	0.02
The First Affiliated Hospital of Bengbu Medical University, China	1.000000	0.02
Liaoning Cancer Hospital and Institute, China	1.000000	0.02
Wuhan Union Hospital, HUST, China	1.000000	0.02
Zhujiang Hospital of Southern Medical University, China	1.000000	0.02
Shandong Cancer Hospital, China	1.000000	0.02
Hospital and Cancer Center, CQU, China	1.000000	0.02
Jiangxi Provincial Maternal and Child Health Hospital, China	1.000000	0.02
Gansu Provincial Hospital, China	1.000000	0.02
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.02
Affiliated Hospital of ZMU, China	1.000000	0.02
Taizhou People's Hospital, China	1.000000	0.02
The First Affiliated Hospital of Nanchang University, China	1.000000	0.02
Tumor Hospital of Guangxi Medical University, China	1.000000	0.02
Jilin Province Cancer Hospital, China	1.000000	0.02
Second Affiliated Hospital, AHMU, China	1.000000	0.02
Linyi Cancer Hospital, China	1.000000	0.02
The First Affiliated Hospital of Xi'an Jiaotong University, XJTU, China	1.000000	0.02
Second Affiliated Hospital of Shanxi Medical University, SXMU, China	1.000000	0.02
The First Affiliated Hospital of Henan University of Science and Technology, China	1.000000	0.02
The Second Clinical Hospital of Jilin University, China	1.000000	0.02
First Hospital of Lanzhou University, LZU, China	1.000000	0.02
Drum Tower Hospital, China	1.000000	0.02
Second Xiangya Hospital, CSU, China	1.000000	0.02
General Hospital of Ningxia Medical University, China	1.000000	0.02
Shaanxi Provincial People's Hospital, China	1.000000	0.02
Affiliated Hospital of Chengde Medical University, China	1.000000	0.02
The First Affiliated Hospital of Wenzhou Medical University, China	1.000000	0.02
Shandong Provincial Hospital, China	1.000000	0.02
Zhongnan Hospital, WHU, China	1.000000	0.02
Harbin Medical University Cancer Hospital, China	1.000000	0.02
Southwest Hospital, Army Medical University, China	1.000000	0.02
The First Hospital of China Medical University, China	1.000000	0.02
Hubei Cancer Hospital (HBCH), China	1.000000	0.02
Anhui Provincial Cancer Hospital, China	1.000000	0.02
Tianjin Central Hospital of Gynecology and Obstetrics, China	1.000000	0.02
Hainan General Hospital, China	1.000000	0.02
The First Affiliated Hospital of Soochow University, China	1.000000	0.02
Qilu Hospital of Shandong University, China	1.000000	0.02
Jinan Central Hospital, China	1.000000	0.02
The First Affiliated Hospital, USTC, China	1.000000	0.02
Suining Central Hospital, China	1.000000	0.02
The Second Affiliated Hospital of Chongqing Medical University, CQMU, China	1.000000	0.02
Xinjiang Tumor Hospital, XJMU, China	1.000000	0.02
Peking University Third Hospital (PUTH), PKUHSC, China	1.000000	0.02
Affiliated Hospital of Guangdong Medical University, GDMU, China	1.000000	0.02
Zhongshan City People's Hospital, China	1.000000	0.02
Hebei People's Hospital, China	1.000000	0.02
Women's Hospital, Zhejiang University School of Medicine, China	1.000000	0.02
First Affiliated Hospital, AHMU, China	1.000000	0.02
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.02
Hunan Cancer Hospital, China	0.500000	0.01
Xiangya School of Medicine, CSU, China	0.500000	0.01

Interested in Oncology and Carcinogenesis?